Cargando...
Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1)
Systemic therapy of advanced hepatocellular carcinoma (HCC) with the small molecule multi-kinase inhibitor sorafenib is associated with large inter-individual pharmacokinetic variability and unpredictable side effects potentially requiring dose reduction or treatment termination. Organic cation tran...
Guardado en:
| Publicado en: | Clin Pharmacol Ther |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6925656/ https://ncbi.nlm.nih.gov/pubmed/31350763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1588 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|